Reducing Plasma Membrane Sphingomyelin Increases Insulin Sensitivity

REFERENCES

• Adams, J. M.II et al. 2004. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25–31.
   PubMed Web of Science ®Google Scholar
• Aerts, J. M. et al. 2007. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56:1341–1349.
   PubMed Web of Science ®Google Scholar
• Chang, L., S. H. Chiang, and A. R. Saltiel. 2004. Insulin signaling and the regulation of glucose transport. Mol. Med. 10:65–71.
   PubMed Web of Science ®Google Scholar
• de Mello, V. D. et al. 2009. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52:2612–2615.
   PubMed Web of Science ®Google Scholar
• Drab, M. et al. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293:2449–2452.
   PubMed Web of Science ®Google Scholar
• Eckel, R. H., S. M. Grundy, and P. Z. Zimmet. 2005. The metabolic syndrome. Lancet 365:1415–1428.
   PubMed Web of Science ®Google Scholar
• Gamard, C. J., G. S. Dbaibo, B. Liu, L. M. Obeid, and Y. A. Hannun. 1997. Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor κB. J. Biol. Chem. 272:16474–16481.
   PubMedGoogle Scholar
• Glaros, E. N. et al. 2007. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem. Pharmacol. 73:1340–1346.
   PubMedGoogle Scholar
• Gorska, M., A. Dobrzyn, M. Zendzian-Piotrowska, and J. Gorski. 2004. Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm. Metab. Res. 36:14–21.
   PubMedGoogle Scholar
• Gustavsson, J. et al. 1999. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 13:1961–1971.
   PubMed Web of Science ®Google Scholar
• Hailemariam, T. K. et al. 2008. Sphingomyelin synthase 2 deficiency attenuates NFκB activation. Arterioscler. Thromb. Vasc. Biol. 28:1519–1526.
   PubMed Web of Science ®Google Scholar
• Han, G. et al. 2009. Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities. Proc. Natl. Acad. Sci. U. S. A. 106:8186–8191.
   PubMed Web of Science ®Google Scholar
• Hanada, K. et al. 1997. A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. J. Biol. Chem. 272:32108–32114.
   PubMedGoogle Scholar
• Hojjati, M. R., and X. C. Jiang. 2006. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J. Lipid Res. 47:673–676.
   PubMed Web of Science ®Google Scholar
• Hojjati, M. R., Z. Li, and X. C. Jiang. 2005. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim. Biophys. Acta 1737:44–51.
   PubMedGoogle Scholar
• Hojjati, M. R. et al. 2005. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280:10284–10289.
   PubMedGoogle Scholar
• Holland, W. L. et al. 2007. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell. Metab. 5:167–179.
   PubMed Web of Science ®Google Scholar
• Holland, W. L., and S. A. Summers. 2008. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29:381–402.
   PubMed Web of Science ®Google Scholar
• Hornemann, T., S. Richard, M. F. Rutti, Y. Wei, and A. von Eckardstein. 2006. Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase. J. Biol. Chem. 281:37275–37281.
   PubMedGoogle Scholar
• Huitema, K., J. van den Dikkenberg, J. F. Brouwers, and J. C. Holthuis. 2004. Identification of a family of animal sphingomyelin synthases. EMBO J. 23:33–44.
   PubMed Web of Science ®Google Scholar
• Ikonen, E., and S. Vainio. 2005. Lipid microdomains and insulin resistance: is there a connection? Sci. STKE 2005:pe3.
   PubMedGoogle Scholar
• Inokuchi, J. 2006. Insulin resistance as a membrane microdomain disorder. Biol. Pharm. Bull. 29:1532–1537.
   PubMedGoogle Scholar
• Ishitsuka, R., A. Yamaji-Hasegawa, A. Makino, Y. Hirabayashi, and T. Kobayashi. 2004. A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes. Biophys. J. 86:296–307.
   PubMedGoogle Scholar
• Itani, S. I., N. B. Ruderman, F. Schmieder, and G. Boden. 2002. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51:2005–2011.
   PubMed Web of Science ®Google Scholar
• Jeong, T. et al. 1998. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest. 101:905–912.
   PubMed Web of Science ®Google Scholar
• Jiang, X. C. et al. 2005. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J. Biol. Chem. 280:18336–18340.
   PubMedGoogle Scholar
• Jiang, X. C. et al. 2000. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 20:2614–2618.
   PubMed Web of Science ®Google Scholar
• Kabayama, K. et al. 2007. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 104:13678–13683.
   PubMed Web of Science ®Google Scholar
• Kralik, S. F., P. Liu, B. J. Leffler, and J. S. Elmendorf. 2002. Ceramide and glucosamine antagonism of alternate signaling pathways regulating insulin- and osmotic shock-induced glucose transporter 4 translocation. Endocrinology 143:37–46.
   PubMedGoogle Scholar
• Landry, Y. D. et al. 2006. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem. 281:36091–36101.
   PubMed Web of Science ®Google Scholar
• Langeveld, M., and J. M. Aerts. 2009. Glycosphingolipids and insulin resistance. Prog. Lipid Res. 48:196–205.
   PubMedGoogle Scholar
• Li, Z. et al. 2007. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochim. Biophys. Acta 1771:1186–1194.
   PubMed Web of Science ®Google Scholar
• Liu, H., Y. Guz, M. H. Kedees, J. Winkler, and G. Teitelman. 2010. Precursor cells in mouse islets generate new beta-cells in vivo during aging and after islet injury. Endocrinology 151:520–528.
   PubMed Web of Science ®Google Scholar
• Liu, J. et al. 2009. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ. Res. 105:295–303.
   PubMed Web of Science ®Google Scholar
• Liu, J., X. Jiang, L. Zhou, H. Wang, and X. Han. 2009. Co-firing of oil sludge with coal-water slurry in an industrial internal circulating fluidized bed boiler. J. Hazard. Mater. 167:817–823.
   PubMed Web of Science ®Google Scholar
• Merrill, A. H.Jr. 1983. Characterization of serine palmitoyltransferase activity in Chinese hamster ovary cells. Biochim. Biophys. Acta 754:284–291.
   PubMedGoogle Scholar
• Merrill, A. H.Jr., and D. D. Jones. 1990. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim. Biophys. Acta 1044:1–12.
   PubMed Web of Science ®Google Scholar
• Mitsutake, S. et al. 2011. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J. Biol. Chem. 286:28544–28555.
   PubMedGoogle Scholar
• Miyaji, M. et al. 2005. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med. 202:249–259.
   PubMedGoogle Scholar
• Muller, G. et al. 2001. Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol. Cell. Biol. 21:4553–4567.
   PubMed Web of Science ®Google Scholar
• Nagao, K. et al. 2007. Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells. J. Biol. Chem. 282:14868–14874.
   PubMedGoogle Scholar
• Park, T. S. et al. 2004. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110:3465–3471.
   PubMed Web of Science ®Google Scholar
• Parpal, S., M. Karlsson, H. Thorn, and P. Stralfors. 2001. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276:9670–9678.
   PubMed Web of Science ®Google Scholar
• Plump, A. S. et al. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343–353.
   PubMed Web of Science ®Google Scholar
• Powell, D. J., E. Hajduch, G. Kular, and H. S. Hundal. 2003. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCζ-dependent mechanism. Mol. Cell. Biol. 23:7794–7808.
   PubMed Web of Science ®Google Scholar
• Razani, B. et al. 2001. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:38121–38138.
   PubMed Web of Science ®Google Scholar
• Saltiel, A. R., and C. R. Kahn. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806.
   PubMed Web of Science ®Google Scholar
• Savage, D. B., K. F. Petersen, and G. I. Shulman. 2007. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87:507–520.
   PubMed Web of Science ®Google Scholar
• Schlitt, A. et al. 2006. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr. Metab. (Lond.) 3:5.
   PubMed Web of Science ®Google Scholar
• Schutze, S. et al. 1992. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown. Cell 71:765–776.
   PubMed Web of Science ®Google Scholar
• Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569–572.
   PubMed Web of Science ®Google Scholar
• Skovbro, M. et al. 2008. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 51:1253–1260.
   PubMed Web of Science ®Google Scholar
• Steppan, C. M. et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307–312.
   PubMed Web of Science ®Google Scholar
• Straczkowski, M. et al. 2004. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53:1215–1221.
   PubMed Web of Science ®Google Scholar
• Stratford, S., D. B. DeWald, and S. A. Summers. 2001. Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem. J. 354:359–368.
   PubMed Web of Science ®Google Scholar
• Tabas, I., K. J. Williams, and J. Boren. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116:1832–1844.
   PubMed Web of Science ®Google Scholar
• Toyoshima, Y. et al. 2005. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology 146:4024–4035.
   PubMedGoogle Scholar
• Turinsky, J., D. M. O'Sullivan, and B. P. Bayly. 1990. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265:16880–16885.
   PubMed Web of Science ®Google Scholar
• Vacaru, A. M. et al. 2009. Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER. J. Cell Biol. 185:1013–1027.
   PubMedGoogle Scholar
• Van der Luit, A. H. et al. 2007. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem. J. 401:541–549.
   PubMedGoogle Scholar
• Virkamaki, A., K. Ueki, and C. R. Kahn. 1999. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest. 103:931–943.
   PubMed Web of Science ®Google Scholar
• Vuguin, P. M. et al. 2006. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 147:3995–4006.
   PubMedGoogle Scholar
• Wang, C. N., L. O'Brien, and D. N. Brindley. 1998. Effects of cell-permeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 47:24–31.
   PubMedGoogle Scholar
• Weiss, B., and W. Stoffel. 1997. Human and murine serine-palmitoyl-CoA transferase: cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur. J. Biochem. 249:239–247.
   PubMedGoogle Scholar
• Weyer, C. et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:1930–1935.
   PubMed Web of Science ®Google Scholar
• Yamaoka, S., M. Miyaji, T. Kitano, H. Umehara, and T. Okazaki. 2004. Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J. Biol. Chem. 279:18688–18693.
   PubMedGoogle Scholar
• Yamashita, T. et al. 2003. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. U. S. A. 100:3445–3449.
   PubMed Web of Science ®Google Scholar
• Yang, X. L., Z. H. Xie, X. J. Jiang, Y. B. Huang, and J. K. Liu. 2009. A new acridone alkaloid from Micromelum integerrimum. Chem. Pharm. Bull. (Tokyo) 57:734–735.
   PubMed Web of Science ®Google Scholar
• Yu, C. et al. 2002. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277:50230–50236.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet, L. et al. 2005. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54:991–999.
   PubMed Web of Science ®Google Scholar
• Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471.
   PubMed Web of Science ®Google Scholar
• Zhao, H. et al. 2007. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56:1210–1218.
   PubMedGoogle Scholar